Overview

Single Ascending Dose Study of ALA-1000

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

An open-label study designed to evaluate the safety, tolerability, and pharmacokinetics of ALA-1000 in opioid-dependent subjects. To characterize the PK profile of ALA-1000 in 5 single ascending dose cohorts and a sixth cohort of single ALA-1000 after receiving buprenorphine sublingual films for 7 days.

Phase:

Phase 1

Details

Lead Sponsor:

Alar Pharmaceuticals Inc.

Treatments:

Buprenorphine